Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Genmab, de Deense parel
Volgen
GENMAB ANNOUNCES YEAR END 2007 FINANCIAL RESULTSwww.genmab.com/upload/11_ar2007_31030...
Is er wat aan het handje vandaag bij Genmab? +6,6%
GENMAB A/S SUMMONS ANNUAL GENERAL MEETING Copenhagen, Denmark; April 7, 2008 – Genmab A/S (OMX: GEN) summon the Annual General Meeting on Wednesday April 23, 2008 at 3:00 pm CEST at the Radisson SAS Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S, Denmark. Agenda: 1. Report of the Board of Directors on the Company’s activities during the year. 2. Presentation of the audited Annual Report 2007 for approval and the discharge of the Board of Directors and the Management. 3. Decision as to the settlement of loss according to the approved Annual Report. 4. Election of members of the Board of Directors. 5. Election of auditor. 6. Proposals from the Board of Directors and/or the shareholders. www.genmab.com/PressCentre/RecentNews...
NOVEL INSIGHTS INTO HUMAX-EGFr MECHANISMS OF ACTION PUBLISHED IN PNAS Copenhagen, Denmark; April 15, 2008 – Genmab A/S (OMX: GEN) announced today new insights showing that HuMax-EGFr™ (zalutumumab) locks epidermal growth factor receptor (EGFr) molecules into a very compact, inactive conformation. The flexibility of the EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective inhibition of cancer cell growth. As EGFr activity plays an important role in many cancers, targeting it with HuMax-EGFr (zalutumumab) should make it especially difficult for cancer cells to grow, multiply, and survive. By using an electron microscope based technique, called protein tomography, the structural rearrangement accompanying inhibition of individual EGFr molecules was studied. Biochemical analyses showed that HuMax-EGFr binds bivalently to the EGFr and, furthermore, was shown to prevent receptor dimerization and to severely limit intermolecular flexibility of EGFr molecules. “These new insights point out that HuMax-EGFr may employ at least three distinct mechanisms of action leading to inhibition of cancer cell growth. HuMax-EGFr is able to induce potent immune system defense activity known as ADCC, block growth factor binding to EGF receptors, and we now established that HuMax-EGFr inhibits EGFR activation by limiting receptor flexibility. This new data further underlines the potential of HuMax-EGFr for treatment of solid cancers.” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. These new findings will be published in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) in the edition published on April 15, 2008. www.genmab.com/PressCentre/RecentNews...
PASSING OF GENMAB A/S' ANNUAL GENERAL MEETING Copenhagen, Denmark; April 23, 2008 - Genmab A/S (OMX: GEN) held its Annual General Meeting, today April 23, 2008 at 3:00 pm at Radisson SAS Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S, Denmark. At the meeting Chairman of the Board Dr. Michael B. Widmer gave - on behalf of the Board - a report on the Company's activities during the past year. Chief Executive Officer and member of the Board, Lisa N. Drakeman presented plans for the year ahead, and Chief Financial Officer Bo Kruse presented the Annual Report for 2007 endorsed by the auditors. The report was approved and discharge was given to the Board and the Management. It was decided that the year's loss of DKK 373 million be carried forward by transfer to accumulated deficit, as stated in the Annual Report. Michael B. Widmer and Karsten Havkrog Pedersen were re-elected to the Board for a further three year period. PricewaterhouseCoopers, Statsautoriseret Revisionsaktieselskab A/S was reelected as the Company's auditor. The General Meeting adopted the proposals from the Board to change the Company's Articles of Association, as follows: * The proposals to remove the current Article 5, Article 6 and Schedule A and to make the consequent amendments to the Articles of Association. * The proposal to amend Article 5 (previously Article 6A) to authorize the Board of Directors to issue additional warrants - without pre-emption rights for the existing shareholders - that give the right to subscribe up to nominally DKK 1,500,000 shares in the Company to members of the Company's Board of Directors, the Company's employees and consultants as well as employees and consultants of the Company's subsidiaries and to implement the corresponding capital increases related to the warrants issued. * The proposal to adopt a new Article 5A to the Articles of Association under which the Board of Directors shall be authorized, until April 23, 2013, by one or more issues to raise loans against bonds or other financial instruments up to a maximum amount of DKK 2 billion, or the equivalent amount in USD or EUR, with a right for the lender to convert his claim to new shares in the Company. * The proposal to amend Article 8 (previously Article 9) so that the requirement of publishing the notice for the General Meeting in a Danish nationwide newspaper is discontinued and the notification is instead published in the computer information system of the Danish Commerce and Companies Agency, by notification to OMX The Nordic Exchange Copenhagen and by posting on the Company's website. * The proposal to amend Article 12 (previously Article 13) to simplify the staggered board election provisions to a more simple election principle so that the members of the Board of Directors elected by the General Meeting shall be elected for a period which expires at the Annual General Meeting in the Company in the third year after the year of their election. * The proposal to adopt a new Article 14 to reflect the adoption of general guidelines for incentive-based remuneration for the Board of Directors and Executive Management. Finally the Board of Directors were authorized according to Section 48 of the Danish Companies Act so that until the next Annual General Meeting the Company may purchase own shares in connection with the buy-back of shares subscribed by employees etc. pursuant to the Company's employee warrant programmes to the extent of up to 2 percent of the Company's share capital and so that the consideration for such shares shall be equal to the exercise price paid for the shares in question. [URL="http://www.genmab.com/PressCentre/RecentNewsReleases/16PassingofGenmabA,-s-,S%27AnnualGeneralMeeting/Language/English.aspx"]Bron[/URL]
SNS Securities The Fantastic Five in Biotech Europe 19 May 2008 Introduction Within the ESN Biotech Universe we have selected five companies that we think will show a better performance than the sector as a whole. In making our selection we specifically looked at important fundamentals for biotechnology companies like: Pipeline development: preferably late stage products in which near term mile stones are to be reached Partnerships: The validation of a pipeline/technology is often underscored if a biotech company managed to sign one or more partnerships with large pharmaceutical or biotechnology companies. It also reduces the risk profile of a company as it often secures the current financial position of a biotech company as well as the financing of future cash burn (milestone payments) Cash position: Most biotech companies in development do not have a steady growing income from revenues. The development of a product is costly and time consuming, which means that a sufficient cash position provides the company with the financial space to finance the development of its pipeline. A low cash position often leads to forced strategic her orientations and weak negotiation power in making partnerships with big pharma. Management: Especially in fast growing companies like biotechs, it is important to have a well experienced management that has the knowledge of business development, closing deals with pharma and commercial experience. However, next to these fundamentals, in the short to medium term it is vital for the share price performance of biotechs to have enough news flow. This, above all things drives the share price. Contrary to most other sectors, the performance of most biotechs is not driven by quarterly figures and the development of the bottom line result. News items that are of importance are usually announcements of partnerships with big pharma, data of clinical trials (Phase I, II, III) and approval/disapprovals of products by the FDA and/or EMEA. In selecting our top picks for this quarter we looked at the news flow that is to be expected in the short to medium term which can drive the share price in the short to medium term. Our top picks for 2008Q2 are: Crucell (NL) Genmab (DK) Intercell (AV) Morphosys (Ger) Transgene (F) Furthermore, per company covered by ESN in European biotech, we have included the news items we can expect in the next few quarters.
Closing in on HuMax-CD20 CLL ph3 data Like the majority of the biotech companies, Genmab has taken some hits during the last 12 months, now trading one-third down from its peak after the record-breaking partner agreement with GSK on the HuMax CD20 programme. We view the current share price as a great opportunity to Buy on anticipation of a positive outcome on the pivotal phase III data from four trials expected before year-end. Based on the previous data presented and the validated technology and targets, we believe the chances of a positive outcome of these trials are good. We believe Genmab is on track to become a profitable biopharmaceutical company, with its very impressive strong late-stage pipeline for the treatment of cancerous and inflammatory diseases. The next 12 months could change the company dramatically, with data expected from four out of the six different phase III studies. The HuMax- CD20 CLL study is expected next month, and data from HuMax-CD20 in NHL, HuMax-EGFr in SCCHN and HuMax-CD4 in CTCL before yearend. The next key event for Genmab is the pivotal data from the HuMax CD20 CLL phase III trial. The previous phase 1/2 “proof of concept” study showed a 50% response in refractory CLL patients and Genmab has indicated that a response of 25% would be enough to get approval. Also keep in mind that the total exposure of the antibody in the phase III study is much higher than in the previous study, which we believe will further increase the odds for a successful outcome. If positive, it could lead to filing for approval in mid-2008 and a possible launch of HuMax CD20 in CLL early 2009. Genmab anticipates ramping up its R&D significantly during 2008. Aside from the HuMax-CD20 development, it clearly looks as if Genmab wants to maximise the value of the still-not-partnered HuMax-EGFr programme. With 17 announced new clinical programmes expected in 2008, five of these are focused on HuMax-EGFr. We expect that a significant partner agreement could see daylight during 2009. Financial guidance for 2008: Revenues of DKK 1.0 billion and a net loss of DKK 800-900 million. Cash position at year-end in the range of DKK 1.7-1.8 billion. Thomas Bowers/ Martin Parkhøi Danske Markets Equities +45 45 12 80 44/+45 45 12 80 46 THBO@danskebank.dk/ MPAR@danskebank.com
flosz schreef:
SNS Securities
The Fantastic Five in Biotech Europe
19 May 2008
Our top picks for 2008Q2 are:
Crucell (NL)
Genmab (DK)
Intercell (AV)
Morphosys (Ger)
Transgene (F)
Furthermore, per company covered by ESN in European biotech, we have included the news items
we can expect in the next few quarters.
Upcoming corporate calendar Top Picks Genmab (GEN DC, DKK 261) Date Product Event Impact June 2008 HuMax CD20 Clinical Phase III data CLL Very important Mid 2008 HuMax EGFr Clinical Phase II data SCCHN front line Important 2008H2 HuMax EGFr Clinical Phase II data NSCLC Very important 2008H2 HuMax CD4 Initiate front line studies Not so important 2008H2 HuMax CD4 Clinical Phase III data CTCL Very important 2008H2 AMG714 Initiate proof of concept Phase II studies Not so important 2008H2 HuMax CD20 Clinical Phase III data NHL Very important 2008H2 HuMax EGFr Initiate Phase III NSCLC front line combined with CRT and RT Important 2008H2 HuMax EGFr Initiate Phase I/II study in colorectal cancer Not so important 2008H2 HuMax CD20 BLA filing CLL Important 2008H2 HuMax EGFr Clinical Phase III data SCCHN Very important 2008H2 HuMax HepC Initiate Phase I/II liver transplants (Hep C) Not important
Flosz, je maakt mijn dag weer goed: Our top picks for 2008Q2 are: Crucell (NL) Crucell (NL) Crucell (NL) Crucell (NL) Genmab (DK) Intercell (AV) Morphosys (Ger) Transgene (F) Psycho
Uit nieuwsbrief biofarmind: Eerste Educatieve Sessie over Monoclonale Antilichamen bijzonder Succesvol O.a. incl. keynote speaker, Jan vd Winkel (Genmab).www.biofarmind.nl/biofarmind/content/...
GENMAB INITIATES STUDY OF ZALUTUMUMAB WITH RADIOTHERAPY IN HEAD AND NECK CANCER Copenhagen, Denmark; June 24, 2008 - Genmab A/S (OMX: GEN) announced today it has initiated a Phase I/II study of zalutumumab (HuMax-EGFr™) in combination with radiotherapy for the treatment of advanced head and neck cancer. The study will include a maximum of 36 patients who are ineligible for platinum based chemotherapy. "Platinum based chemotherapy is currently considered to be the best available standard treatment for advanced head and neck cancer. We hope zalutumumab may some day provide a treatment option for patients who are in need of less toxic therapies," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. About the trial In the dose-escalation part of the study, 6 to 24 patients will be enrolled in cohorts of 3 patients per dose level of zalutumumab. The dose level for each successive cohort will be determined by the aggregate safety data observed in the prior cohorts. When the maximum tolerated dose of zalutumumab is established, an additional cohort of 12 patients will be enrolled and treated at this level. Patients in the study will receive 8 weekly infusions of zalutumumab with the first cohort receiving an initial dose of 12 mg/kg of zalutumumab followed by 7 maintenance doses of 8 mg/kg of zalutumumab in addition to radiotherapy. Patients will be evaluated at 4 weeks following the last dose of zalutumumab and will be followed for a total of 2 years. The objective of the study is to evaluate the safety of repeat dosing and establish the maximum tolerated dose of zalutumumab in combination with radiotherapy in patients with advanced head and neck cancer who are ineligible for platinum based chemotherapy. The primary endpoint of the study is adverse events. www.genmab.com/upload/31_humax-egfr_p...
Waarom wordt er zo negatief gereageerd op dit nieuws? Nu 8,46 % in de min (15:14)
Inmmiddels staat de koers 50% lager dan 12 maanden geleden. Zoals altijd binnen de biophama duurt het allemaal wat langer dan verwacht, maar ik heb de indruk dat er toch geen echte tegenvallers zijn te verwachten. Daarbij zijn de komende maanden cruciaal voor Genmab. Het gaat wel weer erg hard de afgelopen weken. Kan iemand dat verklaren of is dat de verkoopclimax aan het einde van een LT dalende trend (verkopende scheefzittende hedgefunds als GO Capital??) De resultaten van HuMax CD20 kunnen nu ieder moment naar buiten komen. Een positieve uitslag en er komt een shortsqueeze op gang. Dan staan we zo weer op DKK 250+. Ik heb in ieder geval gekocht vandaag op DKK 181,-.
GENMAB REACHES MILESTONE IN OFATUMUMAB COLLABORATION Copenhagen, Denmark; June 30, 2008 – Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20®) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 29 million (approximately USD 6 million) was triggered by treatment of the first patient participating in the Phase II study of ofatumumab for the treatment of relapsing remitting multiple sclerosis (RRMS). “Our collaboration with GSK continues to progress as both companies work towards providing new treatment options for patients,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. “We are pleased to begin treating patients in the first study of ofatumumab in RRMS, an unpredictable and debilitating disease.” Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells. This epitope is different from the other anti-CD20 antibodies currently available or in development. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GSK.
Europe's biotech firms need to think big if they are to prosper, says Lisa Drakeman of Genmabwww.economist.com/people/displaystory...
RECRUITMENT COMPLETED IN OFATUMUMAB CLL FRONT LINE STUDY Copenhagen, Denmark; July 9, 2008 - Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 patients in the Phase II study of ofatumumab (HuMax-CD20®) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients. "We are pleased to complete patient enrollment in the first front line study of ofatumumab and hope to see a positive outcome for the CLL patients in this trial," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. Ofatumumab is an investigational fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 molecule on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 molecule. Ofatumumab is being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country. About the trial Patients in this open label study will be randomized into two treatment groups of 28 patients each. Each patient will receive 6 monthly infusions of either 500 or 1000 mg of ofatumumab in combination with FC. Disease status will be measured every 4 weeks until week 24 according to National Cancer Institute Working Group Guidelines and every 3 months thereafter until disease progression or 24 months. Patients not having progressed on their disease at 24 months will be followed for disease progression at 6 month intervals until 48 months. The objective of the study is to determine the efficacy of ofatumumab in combination with FC in previously untreated CLL patients. The primary endpoint is complete remission measured at any time during the treatment period. Bron: Genmab website (15:22 198DK +9.09%)
Genmab surges on successful drug study with Glaxo Fri Aug 1, 2008 3:28am EDT COPENHAGEN, Aug 1 (Reuters) - Shares in Danish biotech firm Genmab (GEN.CO: Quote, Profile, Research, Stock Buzz) rose by as much as a third on Friday after an experimental treatment for leukaemia it developed with GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) proved effective in a pivotal trial. The companies said late on Thursday the antibody drug met its goal in the study of difficult-to-treat patients with chronic lymphocytic leukaemia (LCC), producing a response rate well in excess of the 25 percent minimum needed. By 0725 GMT, Genmab traded up 26 percent at 324 crowns, after a high of 345, while Glaxo, for which the drug is just one of many in development, added 1.5 percent to 11.93 pounds. Analysts at Lehman Brothers said the results for what would be Genmab's first commercial product were well ahead of expectations and strongly supported a regulatory filing in the fourth quarter of 2008, with potential U.S. launch by mid-2009. The positive results were likely to trigger an estimated $60 million payment to Genmab from Glaxo from the more than $1.1 billion of outstanding milestone payments, they added.
GENMAB ANNOUNCES UPCOMING OFATUMUMAB STUDIES Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies Planned Copenhagen, Denmark; August 25, 2008 - Genmab A/S (OMX: GEN) announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year. "Genmab and GSK have worked diligently to expand the ofatumumab development program to maximize the value of the antibody for patients and shareholders since our collaboration began," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "The new studies we are initiating this year will examine the potential of ofatumumab in Japan as well as a number of new treatment settings - retreatment, maintenance and front line with chlorambucil." www.genmab.com/upload/36_upcoming_ofa...
GENMAB ANNOUNCES CHANGE IN MANAGEMENT Copenhagen, Denmark; September 3, 2008 - Genmab A/S (OMX: GEN) announced today that Claus Møller, M.D., Ph.D. has informed the Board of Directors of his intention to step down from his position as Executive Vice President, Chief Operating Officer of Genmab. Dr. Møller's decision reflects his desire to concentrate on his role as Chairman of the board of IPC-International, Plc and to spend more time with his family having achieved his main career goals within Genmab. Dr. Møller will remain available to Genmab as Development Advisor during a transitional period for the remainder of 2008. The Chief Operating Officer position at Genmab will be discontinued and Dr. Møller's responsibilities will be folded into the research and development department which has already been consolidated under the direction of Prof. Jan G. J. van de Winkel, Ph.D., President, Research and Development and Chief Scientific Officer, in conjunction with an earlier expansion of the company's senior management team which now includes eight members. "Claus was one of Genmab's founders ten years ago and has been an essential part of building Genmab into a world leading biotechnology company. He has made significant contributions across a range of activities including the development of ofatumumab. We wish to offer our sincere thanks to Claus for his many years of service with the company and wish him the best in his future endeavors," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
OFATUMUMAB INDUCES LONG LASTING CLINICAL RESPONSES IN PHASE II RA STUDY Data to be presented at ACR meeting Copenhagen, Denmark; October 8, 2008 – Genmab A/S (OMX: GEN) announced today that data showing that rheumatoid arthritis patients who participated in the ofatumumab (HuMax-CD20®) Phase II study achieved long lasting results at the 48 week follow up period. The data will be presented in a poster session at the ACR/ARHP 2008 Annual Scientific Meeting in San Francisco, California on October 26, 2008. The full abstract can be found at www.abstractsonline.com/plan/ViewAbst... Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site) of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any country.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
876,71
+0,31%
EUR/USD
1,0724
+0,25%
FTSE 100
8.093,19
+0,66%
Germany40^
17.981,90
-0,59%
Gold spot
2.326,20
+0,44%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers